



1614 #7
Dkt. 60623-A/JPW/GJG/CSN

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Adrian Gilbert et al. Examiner: A. DeCloux

U.S. Serial No.: 09/788,131

Group Art Unit: 1614

Filed : February 16, 2001

For : ORAL, NASAL AND PULMONARY DOSAGE FORMULATIONS OF
COPOLYMER 1

1185 Avenue of the Americas
New York, New York 10036
July 2, 2002

RECEIVED

Assistant Commissioner for Patents
Washington, D.C. 20231

JUL 10 2002

SIR:

TECH CENTER 1600/2900

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. §1.97(b)(3)**

In accordance with their duty of disclosure under 37 C.F.R. §1.56, applicants direct the Examiner's attention to the following Reference Items 1-164 (**Exhibits 1-154**) which are listed again on the accompanying Form PTO-1449 (**Exhibit A**). Applicants request that the Examiner review the references and make them of record in the subject application.

This Information Disclosure Statement is being submitted before the issuance of a first Office Action on the merits in connection with the subject application. Accordingly, no fee is required and this Information Disclosure Statement shall be considered pursuant to 37 C.F.R. §1.97(b)(3).

For the convenience of the Examiner, applicants point out that Reference Items 8, 26, 28, 146-148, 156, 160-161, and 163 were cited in the May 24, 2001 International Search Report in the corresponding PCT International Application, and a copy of the Report is enclosed as **Exhibit B**.

Applicants: Adrian Gilbert et al.
Serial No.: 09/788,131
Filed : February 16, 2002
Page 2

Applicants also point out that several of the listed references are counterparts of each other and are cumulative. Therefore, in accordance with 37 C.F.R. § 1.98(c), a counterpart of a reference is identified after the cite to the reference, but a copy of only one of the counterparts is being provided. Applicants will provide the Examiner with copies of any reference upon request.

1. U.S. Patent No. 3,849,550, issued November 19, 1974 (Teitelbaum, et al.) (**Exhibit 1**);
2. U.S. Patent No. 4,339,431, issued July 13, 1982 (Gaffar) (**Exhibit 2**);
3. U.S. Patent No. 5,204,099, issued April 20, 1993 (Barbier, et al.) (**Exhibit 3**);
4. U.S. Patent No. 5,591,629, issued January 7, 1997 (Rodriguez et al.) (**Exhibit 4**);
5. U.S. Patent No. 5,627,206, issued May 6, 1997 (Hupe, et al.) (**Exhibit 5**);
6. U.S. Patent No. 5,668,117, issued September 16, 1997 (Shapiro) (**Exhibit 6**);
7. U.S. Patent No. 5,719,296, issued February 17, 1998 (Acton, III, et al.) (**Exhibit 7**);
8. U.S. Patent No. 5,800,808, issued September 1, 1998 (Konfino,

Applicant Adrian Gilbert et al.
Client Teva (2609) File No. 60623-A Atty. JPW/GJG/CSN
Date July 2, 2002

Kindly acknowledge receipt of the accompanying


Information Disclosure Statement in connection with Adrian Gilbert et al., ORAL, NASAL AND PULMONARY DOSAGE FORMULATIONS OF COPOLYMER 1, U.S. Serial No. 09/788,131, filed February 16, 2001, including Form-PTO 1449 as **Exhibit A**, a copy of the International Search Report in the corresponding PCT International Application as **Exhibit B**, **Exhibits 1-154**, and a Certificate of Mailing dated July 2, 2002.

by placing your receiving date stamp hereon and returning to us.

Applicant Adrian Gilbert et al. SML
Client Teva (2609) File No. 60623-A Atty. JPW/GJG/CSN
Date July 2, 2002

Kindly acknowledge receipt of the accompanying

Information Disclosure Statement in connection with Adrian Gilbert et al., ORAL, NASAL AND PULMONARY DOSAGE FORMULATIONS OF COPOLYMER 1, U.S. Serial No. 09/788,131, filed February 16, 2001, including Form-PTO 1449 as **Exhibit A**, a copy of the International Search Report in the corresponding PCT International Application as **Exhibit B**, **Exhibits 1-154**, and a Certificate of Mailing dated July 2, 2002.



by placing your receiving date stamp hereon and returning to us.